Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant | Zendy

Wilbur H. Chen | Zendy; Lisa A. Jackson | Zendy; Kathryn M. Edwards | Zendy; Wendy A. Keitel | Zendy; Heather Hill | Zendy; Diana L. Noah | Zendy; C. Buddy Creech | Zendy; Shital M. Patel | Zendy; Brian Mangal | Zendy; Karen L. Kotloff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

Author(s) -

Wilbur H. Chen,

Lisa A. Jackson,

Kathryn M. Edwards,

Wendy A. Keitel,

Heather Hill,

Diana L. Noah,

C. Buddy Creech,

Shital M. Patel,

Brian Mangal,

Karen L. Kotloff

Publication year - 2015

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00475-15

Subject(s) - adjuvant , immunogenicity , vaccination , influenza a virus subtype h5n1 , virology , medicine , live attenuated influenza vaccine , influenza vaccine , pandemic , virus , immunology , antibody , covid-19 , disease , infectious disease (medical specialty)

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research